Alkermes (NASDAQ:ALKS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Alkermes (NASDAQ:ALKS) had its target price upped by analysts at Wells Fargo & Company from $37.00 to $43.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 42.51% from the stock’s current price.

Several other brokerages have also commented on ALKS. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Wall Street Zen lowered Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 9th. Truist Financial raised their price objective on shares of Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Wolfe Research began coverage on shares of Alkermes in a research note on Monday. They issued an “outperform” rating and a $45.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.07.

Alkermes Stock Performance

Shares of NASDAQ:ALKS traded down $0.87 during trading on Thursday, reaching $30.17. The stock had a trading volume of 745,544 shares, compared to its average volume of 2,004,099. Alkermes has a 52 week low of $25.17 and a 52 week high of $36.32. The firm’s fifty day moving average is $31.44 and its 200 day moving average is $30.17. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of 14.94 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to analyst estimates of $380.44 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. Alkermes’s quarterly revenue was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, research analysts forecast that Alkermes will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the transaction, the director owned 103,744 shares of the company’s stock, valued at $3,586,430.08. The trade was a 37.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $33.93, for a total value of $305,370.00. Following the sale, the executive vice president owned 57,740 shares of the company’s stock, valued at $1,959,118.20. This trade represents a 13.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 148,148 shares of company stock worth $5,028,378 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada lifted its position in shares of Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after purchasing an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Alkermes in the 1st quarter worth about $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock valued at $15,927,000 after buying an additional 20,091 shares during the last quarter. State of New Jersey Common Pension Fund D increased its stake in Alkermes by 15.1% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,677 shares of the company’s stock valued at $1,793,000 after buying an additional 8,214 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Alkermes by 1.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock worth $1,249,000 after buying an additional 551 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

More Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $45 price target, signaling analyst conviction in upside versus the current level. Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation
• Neutral Sentiment: Alkermes announced a CEO succession plan: long‑time CEO Richard Pops will retire effective July 31, 2026 and EVP/COO Blair Jackson will become CEO on Aug. 1, 2026; Pops will remain chairman — provides leadership clarity but raises integration/execution questions ahead of the Avadel integration. Alkermes plc Announces CEO Succession Plan
• Neutral Sentiment: Company is presenting at upcoming conferences (TD Cowen) and recently closed the Avadel transaction, items investors should watch for slides/management commentary on integration and revenue contribution. Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Q4 results: Alkermes reported EPS of ~$0.29, below consensus (~$0.43) while revenue (~$384.6M) was roughly in line/slightly ahead of estimates but down ~10.6% year‑over‑year — an earnings miss that weighs on near‑term investor sentiment. Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 guidance was updated to a negative EPS range (‑0.798 to ‑0.680), far below Street expectations (consensus ~1.63), creating significant near‑term earnings uncertainty and likely driving most of the downward price pressure. Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
• Neutral Sentiment: Short‑interest data reported in some feeds appears inconsistent/invalid (zero/NaN values) and shouldn’t be relied on for a constructive signal today. Listen to Conference Call / View Press Release

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.